The downgrade from Goldman Sachs, a major financial institution, could negatively impact investor sentiment towards Organon. The significant reduction in the price target from $33 to $16 suggests that Goldman Sachs sees less potential for growth in the stock, which could lead to a decrease in its price in the short term.